|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's Range||6.04 - 6.49|
|52 Week Range||1.27 - 19.20|
|Beta (5Y Monthly)||1.15|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 14, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Company's successful fundraising and inclusion in the Russell Microcap(R) Index comes after a series of promising test results for its COVID-19 drug candidates Shelton, Connecticut--(Newsfile Corp. - July 23, 2020) - NanoViricides, Inc. (NYSE American: NNVC) (the "Company") is a development stage, nano-biopharmaceutical Company, with proprietary research focused on countering viral diseases. The Company's lead drug candidate, a topical cream for shingles, has been at the cusp of the IND (Investigational New Drug) application ...
SHELTON, CT / ACCESSWIRE / July 21, 2020 / NanoViricides, Inc.
SAN FRANCISCO, July 20, 2020 -- Hagens Berman urges investors in NanoViricides, Inc. (NNVC) to submit their losses now. The firm is investigating possible securities fraud, and.